The description of the clinical observation of the successful therapy with ibrutinib recurrent B-cell chronic lymphocytic leukemia associated with autoimmune complications is given. The reasons for occurrence the autoimmune complications of CLL, their effect on the disease prognosis as well as the tactics of conducting similar patients have been considered
Ibrutinib and other targeted inhibitors of B-cell receptor signaling achieve impressive clinical res...
Autoimmune cytopenias are a frequent complication in CLL, occuring in approximately 5-10% of the pat...
A major revolution in the treatment of chronic lymphocytic leukemia (CLL) began with the approval of...
Autoimmune complications are common in chronic lymphocytic leukemia (CLL), occurring in up to a quar...
The majority of disease-specific complications in chronic lymphocytic leukemia (CLL), notably infect...
The clinical course of chronic lymphocytic leukemia (CLL) may be complicated at any time by autoimmu...
The aim of this multicenter GIMEMA study was to correlate autoimmune complications (AIC) in B-cell c...
Purpose of the study. To obtain experience with ibrutinib in patients with chronic lymphocytic leuke...
Autoimmune cytopenias (AIC) affect 5-9% of patients with chronic lymphocytic leukemia (CLL). Targete...
Introduction Autoimmune cytopenia (AIC) is relatively common in patients with chronic lymphocytic le...
Autoimmune cytopenias (AICs) affect 5% to 9% of patients with chronic lymphocytic leukemia (CLL). Ta...
The treatment landscape of chronic lymphocytic leukemia (CLL) has been challenged by the advent of n...
“Accelerated” chronic lymphocytic leukemia/small lymphocytic lymphoma (A-CLL) is a rare histological...
Fifty-two cases of autoimmune hemolytic anemia (AHA) were observed within a series of 1203 patients ...
Ibrutinib has demonstrated a significant clinical impact in patients with de novo and relapsed/refra...
Ibrutinib and other targeted inhibitors of B-cell receptor signaling achieve impressive clinical res...
Autoimmune cytopenias are a frequent complication in CLL, occuring in approximately 5-10% of the pat...
A major revolution in the treatment of chronic lymphocytic leukemia (CLL) began with the approval of...
Autoimmune complications are common in chronic lymphocytic leukemia (CLL), occurring in up to a quar...
The majority of disease-specific complications in chronic lymphocytic leukemia (CLL), notably infect...
The clinical course of chronic lymphocytic leukemia (CLL) may be complicated at any time by autoimmu...
The aim of this multicenter GIMEMA study was to correlate autoimmune complications (AIC) in B-cell c...
Purpose of the study. To obtain experience with ibrutinib in patients with chronic lymphocytic leuke...
Autoimmune cytopenias (AIC) affect 5-9% of patients with chronic lymphocytic leukemia (CLL). Targete...
Introduction Autoimmune cytopenia (AIC) is relatively common in patients with chronic lymphocytic le...
Autoimmune cytopenias (AICs) affect 5% to 9% of patients with chronic lymphocytic leukemia (CLL). Ta...
The treatment landscape of chronic lymphocytic leukemia (CLL) has been challenged by the advent of n...
“Accelerated” chronic lymphocytic leukemia/small lymphocytic lymphoma (A-CLL) is a rare histological...
Fifty-two cases of autoimmune hemolytic anemia (AHA) were observed within a series of 1203 patients ...
Ibrutinib has demonstrated a significant clinical impact in patients with de novo and relapsed/refra...
Ibrutinib and other targeted inhibitors of B-cell receptor signaling achieve impressive clinical res...
Autoimmune cytopenias are a frequent complication in CLL, occuring in approximately 5-10% of the pat...
A major revolution in the treatment of chronic lymphocytic leukemia (CLL) began with the approval of...